Latest Ipo And Capital Markets News

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

Infragreen Group Limited reported a robust 190% increase in revenue for FY25 following its successful IPO, despite a significant statutory net loss. The company’s strategic acquisitions and expanded ownership stakes underpin a promising outlook in sustainable infrastructure.